SCHEMBL146053

SCHEMBL146053

COc1ccc2nc(-c3cc(C)c(OCCO)c(C)c3)[nH]c(=O)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.54
KDM4E B2RXH2 2/20 0.54
LMNA P02545 1/20 0.54
HSD17B10 Q99714 1/20 0.54
PARP1 P09874 3/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
IL17A Q16552 1/20 0.49
TNKS O95271 2/20 0.48
TNKS2 Q9H2K2 2/20 0.48
GUSB P08236 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30052315 1.00 BRD4 (0.54) BRD4KDM4ELMNAHSD17B10PARP1
SCHEMBL121722 0.91 BRD4 (0.57) BRD4PARP1HDAC1HDAC3HDAC4
SCHEMBL30434551 0.91 BRD4 (0.57) BRD4PARP1HDAC1HDAC3HDAC4
SCHEMBL378054 0.90 KDM4E (0.53) BRD4KDM4ELMNAHSD17B10PARP1
SCHEMBL348771 0.86 PARP1 (0.48) BRD4PARP1HDAC1HDAC3HDAC4
SCHEMBL346585 0.86 TNKS (0.48) BRD4PARP1HDAC1HDAC3HDAC4
SCHEMBL377651 0.85 BRD4 (0.70) BRD4KDM4ELMNAHSD17B10IL17A
SCHEMBL144139 0.84 BRD4 (0.56) BRD4KDM4ELMNAPARP1HDAC1
SCHEMBL30055885 0.84 BRD4 (0.56) BRD4KDM4ELMNAPARP1HDAC1
SCHEMBL30053518 0.84 CYP1B1 (0.56) HSD17B10PARP1TNKSTNKS2GUSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190091235-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2019-03-28 US claimed
US-10111885-B2 Compositions and therapeutic methods for the treatment of complement-associated diseases RESVERLOGIX CORP. (CA) 2018-10-30 US claimed
EP-2421533-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2018-10-17 EP claimed
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2018-04-19 US claimed
EP-3268007-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES Resverlogix Corp. (CA) 2018-01-17 EP claimed
US-9757368-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2017-09-12 US claimed
US-20160346291-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION RESVERLOGIX CORP (CA) 2016-12-01 US claimed
WO-2016147053-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES RESVERLOGIX CORP. (CA) 2016-09-22 WO claimed
US-20160263126-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2016-09-15 US claimed
EP-3035933-A2 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION Resverlogix Corporation (CA) 2016-06-29 EP claimed
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 US claimed
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-03-08 US claimed
US-8114995-B2 Methods of preparing quinazolinone derivatives RESVERLOGIX CORP. (CA) 2012-02-14 US claimed
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. 2012-01-19 US claimed
US-8053440-B2 Compounds for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2011-11-08 US claimed
JP-2011526287-A 2011-10-06 JP claimed
EP-2346837-A1 METHODS OF PREPARING QUINAZOLINONE DERIVATIVES RESVERLOGIX CORP. (CA) 2011-07-27 EP claimed
US-20100004448-A1 METHODS OF PREPARING QUINAZOLINONE DERIVATIVES RESVERLOGIX CORP. (CA) 2010-01-07 US claimed
WO-2009158404-A1 METHODS OF PREPARING QUINAZOLINONE DERIVATIVES RESVERLOGIX CORP. (CA) 2009-12-30 WO claimed
US-20080188467-A1 To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists HEPALINK (HONG KONG) LIMITED (HK) 2008-08-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 BRD4 1910/4885KDM4E 4404/4885LMNA 489/4885
US-10111885-B2 Compositions and therapeutic methods for the treatment of complement-associated diseases C5, CFH, C1QBP BRD4 3811/4885KDM4E 3741/4885LMNA 1392/4885
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION BRD4, BMI1, BRPF3 BRD4 1/4885KDM4E 202/4885LMNA 1294/4885
US-20160346291-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION PCSK9, TGFB1, HMGCR BRD4 3081/4885KDM4E 1562/4885LMNA 1558/4885
US-20120059002-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 192/4885KDM4E 3020/4885LMNA 3416/4885
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 BRD4 1910/4885KDM4E 4404/4885LMNA 489/4885
US-20160263126-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES C5, CFH, C1QBP BRD4 3811/4885KDM4E 3741/4885LMNA 1392/4885
US-20100004448-A1 METHODS OF PREPARING QUINAZOLINONE DERIVATIVES APOB, APOL1, LDLR BRD4 1306/4885KDM4E 3883/4885LMNA 88/4885
US-20190091235-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES C5, CFH, C1QBP BRD4 3811/4885KDM4E 3741/4885LMNA 1392/4885
US-20080188467-A1 To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists APOB, LDLR, APOL1 BRD4 693/4885KDM4E 2993/4885LMNA 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.